12.71 0.00 (0.00%)
After hours: 5:10PM EDT
|Bid||9.87 x 2900|
|Ask||14.45 x 800|
|Day's Range||12.66 - 13.32|
|52 Week Range||5.42 - 15.08|
|PE Ratio (TTM)||35.31|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a per-share basis, the Mountain View, California-based company said it had a loss of 19 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
ChemoCentryx Inc (NASDAQ:CCXI) is trading with a trailing P/E of 32.9x, which is higher than the industry average of 27.1x. While CCXI might seem like a stock to avoid orRead More...
ChemoCentryx Inc (NASDAQ:CCXI) delivered an ROE of 22.53% over the past 12 months, which is an impressive feat relative to its industry average of 17.94% during the same period. WhileRead More...
ChemoCentryx Inc’s (NASDAQ:CCXI): ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The US$535.95M market-cap posted a loss in itsRead More...
The Mountain View, California-based company said it had profit of 80 cents per share. The biopharmaceutical company posted revenue of $56.3 million in the period. For the year, the company reported net ...
Categories: Yahoo FinanceGet free summary analysis ChemoCentryx, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ChemoCentryx, Inc. – Fortress Biotech, Inc., Teva Pharmaceutical Industries Limited Sponsored ADR and Pfizer Inc. (FBIO-US, TEVA-US and PFE-US) that have also reported for this period. Highlights Summary numbers: ... Read more (Read more...)
ChemoCentryx Inc (NASDAQ:CCXI), a biotechnology company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs of $8.42Read More...
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives ChemoCentryx, Inc. a score of 21. Our analysis is based on comparing ChemoCentryx, Inc. with the following peers – Fortress Biotech, Inc., Biogen Inc., Johnson & Johnson, AbbVie, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Amgen Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Pfizer Inc. and ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for ChemoCentryx, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ChemoCentryx, Inc. Here are 5 ETFs with the largest exposure to CCXI-US. Comparing the performance and risk of ChemoCentryx, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
If you are looking to invest in ChemoCentryx Inc’s (NASDAQ:CCXI), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...
ChemoCentryx Inc (NASDAQ:CCXI), a pharmaceuticals, biotechnology and life sciences company based in United States, saw a decent share price growth in the teens level on the NasdaqGS over the lastRead More...